Introduction
Isoflavones have been a subject of intensive researches that have evaluated their possible hypocholesterolemic effects, antioxidant effects, and estrogen-like effects on blood vessels (Kapiotis et al., 1997; Nestel et al., 1997) . Investigations in regards to animals and in humans have suggested that dietary soy protein containing isoflavones reduce blood pressure, improve lipid profiles, and restore vascular function (Teede et al., 2001) . The 3 major isoflavones found in soybeans are genistein (4',5,7-trihydroxyisoflavone), daidzein (4',7-dihydroxyisoflavone), and glycitein (6-methoxydaidzein). Soy protein containing isoflavones has been observed to have several beneficial effects on cardiovascular health; a meta-analysis study showed that total cholesterol decreased by 9.3%, triglyceride by 10.5% and low-density lipoprotein cholesterol by 12.9%, when an average of 47 g of soy protein was consumed daily (Anderson et al., 1995) . Soybean isoflavones were suggested to inhibit proliferation of vascular smooth muscle and thus contribute to the prevention of atherosclerotic cardiovascular diseases (Pan et al., 2001 ).
The small guanosine triphosphatase RhoA plays an important role as a molecular switch in the enhancement of Ca 2+ sensitivity of smooth muscle contraction (Hirata et al., 1992) . Activated RhoA increases the Ca 2+ sensitivity of both MLC phosphorylation and contractions in smooth muscle (Gong et al., 1995) . Rho-kinase is an effector of the small GTP-binding protein RhoA and is a major cellular regulator for agonist-induced Ca 2+ -sensitization in smooth muscle contraction. Rho-kinase directly phosphorylates the myosin phosphatase targeting subunit 1 (MYPT1) at Thr855 of myosin light-chain phosphatase (MLCP) and consequently inhibits phosphatase activity. Rho-kinase also phosphorylates protein kinase C (PKC)-potentiated inhibitory protein for heterotrimeric MLCP of 17 kDa (CPI17) (Eto et al., 1995) , which directly inhibits the catalytic domain of MLCP. CPI17 can be phosphorylated by both Rho-kinase and PKC.
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Genistein and daidzein prevented agonist-induced vascular contraction in isolated rat aortic rings (Vera et al., 2005) . There are few reports exhibiting whether isoflavones exert vasorelaxation by modulating the RhoA/Rho-kinase signaling pathway or phosphorylation of MYPT1 or CPI17.
It was hypothesized that isoflavone attenuates vascular contraction by inhibiting the RhoA/Rho-kinase signaling pathway. Therefore, the purpose of present study was to investigate the inhibitory effects of isoflavones on RhoA activation and subsequent phosphorylation of MYPT1 or CPI17, as well as on vascular smooth muscle contraction induced by U46619 or KCl.
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Tissue preparation and tension measurement
The investigation is in accordance with Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (Health, 1996) . Male SpragueDawley rats, weighing 320-350 g, were used. With animals under anesthesia (sodium pentobarbital 50 mg kg -1 i.p.), the thoracic aorta was immediately excised and immersed in an ice-cold, modified Krebs solution composed of (in mM) NaCl, 115.0;
KCl, 4.7; CaCl 2 , 2.5; MgCl 2 , 1.2; NaHCO 3 , 25.0; KH 2 PO 4 , 1.2; and dextrose, 10.0. The aorta was cleaned of all adherent connective tissue on wet filter paper, soaked in the Krebs-bicarbonate solution and cut into four ring segments (4 mm in length) as described by Seok et al (Seok et al., 2006) . All rings were denuded of endothelium by gently rubbing the internal surface with the edge of forceps. Two stainless-steel triangles were inserted through each vessel ring. Care was taken to avoid rubbing the endothelial surface of the vessels that had intact endothelium. Each aortic ring was suspended in a water-jacketed organ bath (22 ml) maintained at 37°C and aerated with a mixture of 95% O 2 and 5% CO 2 . One triangle was anchored to a stationary support, and the other was connected to an isometric force transducer (Grass FT03C, Quincy, Mass., USA). The rings were stretched passively by imposing the optimal resting tension, 2.0 g, which was maintained throughout the experiment. Each ring was equilibrated in the organ bath solution for 90 min before the experiment involving the contractile response to 50 mM of KCl. Isometric contractions were recorded using a 
Western blot
After functional study, muscle strips were quickly immersed in acetone containing 10% trichloroacetic acid (TCA) and 10 mM dithiothreitol (DTT) precooled to -80°C. The aortic rings were washed in acetone containing 5 mM DTT to remove TCA, air-dried and stored at -80°C until use. Previously stored samples were homogenized in a buffer containing 320 mM sucrose, 50 mM TRIS, 1 mM EDTA, 1% Triton X-100, 1 mM DTT, and protease inhibitors leupeptin (10 µ g/ml), trypsin inhibitor (10 µ g/ml), aprotinin (2 µ g/ml), phenylmethylsulphonyl fluoride (PMSF; 100 µ g/ml) and phosphatase inhibitor 
Inhibitory effect of genistein or daidzein on U46619-or KCl-induced RhoA activation
After pretreatment with genistein, daidzein or vehicle for 30 minutes, the addition of U46619 (30 nM) or KCl (50 mM) induced contractions, reaching a plateau in 10 min.
We freeze-clamped aortic rings contracted with U46619 or KCl and determined the amounts of GTP-RhoA by using RhoA G-LISA TM Activation Assay. U46619 or KCl increased GTP-RhoA as compared with the basal level (2.60 ± 0.55 fold or 1.83 ± 0.10 fold, respectively) in endothelium-denuded aortic rings ( response to 50 mM KCl. Pretreatment with Ro31-8220, a PKC inhibitor, inhibited the vascular contractility and phosphorylation of CPI17 Thr38 in response to PDBu. However, both genistein and daidzein had no effect on the PDBu-induced vascular contraction and CPI17 phosphorylation (Fig. 6 ).
This article has not been copyedited and formatted. The final version may differ from this version. The activity of myosin phosphatase decreases when PKC-potentiated inhibitory protein for heterotrimeric MLCP of 17 kDa (CPI17) or MYPT1 is phosphorylated (Feng et al., 1999; Ito et al., 2004 CPI17 is another potential mediator of Ca 2+ sensitization that is independent of MYPT1 phosphorylation. CPI17 is a 17-kDa peptide, first isolated from porcine aorta (Eto et al., 1995) , in which phosphorylation enhances its potency for inhibiting the catalytic subunit of myosin phosphatase (Seko et al., 2003; Pang et al., 2005 phosphorylation and contractions. These reports showed that U46619 caused CPI17 phosphorylation through activation of the RhoA/Rho-kinase pathway. Our data also showed that U46619 significantly increased CPI17 Thr38 phosphorylation, which was inhibited by both genistein and daidzein (Fig. 5) . Daidzein inhibited CPI17 Thr38 phosphorylation induced by phenylephrine (data not shown).
Genistein and daidzein are structurally very similar, differing only in the substitution at position 5 (a hydroxyl group absent in daidzein) (Nakashima et al., 1991) . The difference shows that genistein is a well known inhibitor of a broad range of tyrosine kinase, whereas daidzein lacks inhibitory activity regarding the tyrosine kinase.
However, both genistein and daidzein inhibited Rho-kinase and vascular contractions, suggesting that the inhibitory action of genistein or daidzein is independent of tyrosine kinase inhibition. Although isoflavones suppressed GTP RhoA activation induced by U46619
and KCl, the molecular mechanism by which isoflavones inhibit RhoA activation remains to be elucidated. GDP dissociation inhibitors (RhoGDI), guanine nucleotide exchange factors (GEFs), Rho GTPase activating proteins (RhoGAPs), and GTP RhoA It has recently been proven that activation of the RhoA/Rho-kinase signal transduction pathway is one of the principal mechanisms of vasoconstriction in arterial hypertension, and that this pathway is a novel therapeutic target for regulating arterial hypertension (Johns et al., 2000) .
In conclusion, isoflavone attenuates vascular contraction by inhibiting RhoA/Rhokinase signaling. These results suggest that isoflavone inhibited vascular contractions in response to U46619 or KCl, through dysinhibition of MLCP, by inhibiting activation of RhoA and the subsequent phosphorylation of MYPT1 Thr855 and CPI17 Thr38 .
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